Infinity Pharma 
Welcome,         Profile    Billing    Logout  
 4 Products   81 Diseases  4 Products   5 Trials   314 News 
5 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
eganelisib (IPI-549) / Infinity Pharma
NCT03795610: Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma

Recruiting
2
15
US
IPI-549
Ezra Cohen, The V Foundation for Cancer Research
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Cancer Stage IV, Head and Neck Cancer Stage III, HPV-Related Carcinoma, HPV-Related Malignancy, HPV-Related Squamous Cell Carcinoma
06/23
06/23
MARIO-3, NCT03961698: Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

Checkmark Early data from MARIO-3 trial in combination with IPI-549 for 1L RCC
Dec 2021 - Dec 2021: Early data from MARIO-3 trial in combination with IPI-549 for 1L RCC
Hourglass Jun 2021 - Jun 2021 : Additional data from MARIO-3 trial in combination with Abraxane and IPI-549 for 1L TNBC at ASCO 2021
Checkmark From MARIO-3 trial in combination with IPI-549 + Abraxane for 1L TNBC
Dec 2020 - Dec 2020: From MARIO-3 trial in combination with IPI-549 + Abraxane for 1L TNBC
Active, not recruiting
2
91
US
IPI-549 (eganelisib), Atezolizumab, Tecentriq, nab-paclitaxel, Abraxane, Bevacizumab, Avastin
Infinity Pharmaceuticals, Inc., Roche Pharma AG
Breast Cancer, Renal Cell Carcinoma
08/23
08/23
NCT02637531: A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Checkmark From MARIO-1 trial in combination with IPI-549 for solid tumors
Nov 2020 - Nov 2020: From MARIO-1 trial in combination with IPI-549 for solid tumors
Checkmark From P1/1b trial in combination with IPI-549 for advanced solid tumors
Nov 2020 - Nov 2020: From P1/1b trial in combination with IPI-549 for advanced solid tumors
Checkmark Clinical & translational data from expansion cohorts of MARIO‑1 phase 1b study in combination with Opdivo
More
Active, not recruiting
1
219
US
IPI-549 (eganelisib), Nivolumab, OPDIVO
Infinity Pharmaceuticals, Inc.
Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G), High-circulating Myeloid-derived Suppressor Cells (Part H)
01/22
12/22
NCT06533761: Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

Recruiting
1
125
Europe, US
Eganelisib, Eganelisib in combination with cytarabine
Stelexis BioSciences
AML, Adult, MDS
07/27
03/28
patidegib topical (IPI-926 topical) / Bridge Biotherap, LEO Pharma
NCT06050122: Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults with Gorlin Syndrome

Recruiting
3
140
Europe, US
Patidegib Topical Gel, Patidegib, IPI-926, Saridegib, SGT-610, Patidegib Topical Gel with no active patidegib, Vehicle Gel, Placebo
Sol-Gel Technologies, Ltd., Premier Research Group plc
Gorlin Syndrome
12/25
12/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
eganelisib (IPI-549) / Infinity Pharma
NCT03795610: Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma

Recruiting
2
15
US
IPI-549
Ezra Cohen, The V Foundation for Cancer Research
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Cancer Stage IV, Head and Neck Cancer Stage III, HPV-Related Carcinoma, HPV-Related Malignancy, HPV-Related Squamous Cell Carcinoma
06/23
06/23
MARIO-3, NCT03961698: Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

Checkmark Early data from MARIO-3 trial in combination with IPI-549 for 1L RCC
Dec 2021 - Dec 2021: Early data from MARIO-3 trial in combination with IPI-549 for 1L RCC
Hourglass Jun 2021 - Jun 2021 : Additional data from MARIO-3 trial in combination with Abraxane and IPI-549 for 1L TNBC at ASCO 2021
Checkmark From MARIO-3 trial in combination with IPI-549 + Abraxane for 1L TNBC
Dec 2020 - Dec 2020: From MARIO-3 trial in combination with IPI-549 + Abraxane for 1L TNBC
Active, not recruiting
2
91
US
IPI-549 (eganelisib), Atezolizumab, Tecentriq, nab-paclitaxel, Abraxane, Bevacizumab, Avastin
Infinity Pharmaceuticals, Inc., Roche Pharma AG
Breast Cancer, Renal Cell Carcinoma
08/23
08/23
NCT02637531: A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Checkmark From MARIO-1 trial in combination with IPI-549 for solid tumors
Nov 2020 - Nov 2020: From MARIO-1 trial in combination with IPI-549 for solid tumors
Checkmark From P1/1b trial in combination with IPI-549 for advanced solid tumors
Nov 2020 - Nov 2020: From P1/1b trial in combination with IPI-549 for advanced solid tumors
Checkmark Clinical & translational data from expansion cohorts of MARIO‑1 phase 1b study in combination with Opdivo
More
Active, not recruiting
1
219
US
IPI-549 (eganelisib), Nivolumab, OPDIVO
Infinity Pharmaceuticals, Inc.
Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G), High-circulating Myeloid-derived Suppressor Cells (Part H)
01/22
12/22
NCT06533761: Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

Recruiting
1
125
Europe, US
Eganelisib, Eganelisib in combination with cytarabine
Stelexis BioSciences
AML, Adult, MDS
07/27
03/28
patidegib topical (IPI-926 topical) / Bridge Biotherap, LEO Pharma
NCT06050122: Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults with Gorlin Syndrome

Recruiting
3
140
Europe, US
Patidegib Topical Gel, Patidegib, IPI-926, Saridegib, SGT-610, Patidegib Topical Gel with no active patidegib, Vehicle Gel, Placebo
Sol-Gel Technologies, Ltd., Premier Research Group plc
Gorlin Syndrome
12/25
12/25

Download Options